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Abstract
Background: Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted
standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to
pegylated G-CSF (Neulasta®, Amgen) with sustained release properties. This is a randomized, comparative, double-
blind, multicenter study to evaluate efficacy and safety of RGB-02 in breast cancer patients receiving cytotoxic
regimen.
Methods: Two hundred thirty-nine women presenting with breast cancer were randomized to RGB-02 (n = 121)
and the reference product (n = 118). All patients received up to 6 cycles of docetaxel/doxorubicin chemotherapy
combination and a once-per-cycle injection of a fixed 6 mg dose of pegfilgrastim. Primary endpoint was the
duration of severe neutropenia (ANC < 0.5 × 109/L) in Cycle 1 (2-sided CI 95%). Secondary endpoints included
incidence and duration of severe neutropenia (in cycles 2–4), incidence of febrile neutropenia, time to ANC
recovery, depth of ANC nadir, and safety outcomes.
Results: The mean duration of severe neutropenia in Cycle 1 was 1.7 (RGB-02) and 1.6 days (reference), with a
difference (LS Mean) of 0.1 days (95% CI -0.2, 0.4). Equivalence could be established as the CI for the difference in LS
Mean lay entirely within the pre-defined range of ±1 day. This positive result was supported by the analysis of
secondary endpoints, which also revealed no clinical meaningful differences. Safety profiles were comparable
between groups. No neutralizing antibodies against pegfilgrastim were identified.
Conclusions: Treatment equivalence in reducing the duration of chemotherapy induced neutropenia between
RGB-02 and Neulasta® could be demonstrated. Similar efficacy and safety profiles of the once-per-cycle
administration of RGB-02 and the pegfilgrastim reference were demonstrated.
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Therapeutic equivalence
Background
RGB-02 (Gedeon Richter) is a proposed biosimilar
medicinal product to Neulasta® (Amgen) which has
been approved in the European Union (EU) in 2002
and is commonly used to decrease the duration of
chemotherapy-induced neutropenia and to reduce the
probability of febrile neutropenic episodes in patients
treated with cytotoxic chemotherapy for malignancy.
The active substance of RGB-02 is pegfilgrastim, the
pegylated form of filgrastim, which constitutes a cova-
lent conjugate of recombinant human granulocyte-col-
ony stimulating factor (G-CSF) with a single 20 kDa
polyethylene glycol (PEG) [1]. Filgrastim, approved in
1991 is a non-glycosylated protein with a methionine
group attached to the human amino acid sequence
and is produced by recombinant-DNA technology in
Escherichia coli. Filgrastim is eliminated from the cir-
culation by rapid renal clearance therefore requires
daily administration in each chemotherapy cycle [2].
In contrast, pegfilgrastim is mainly eliminated by
neutrophil-mediated clearance, resulting in a long
serum half-life and therefore allows a single adminis-
tration per chemotherapy-cycle [3, 4]. This clear ad-
vantage over filgrastim which has to be administered
daily, leads to a better patient compliance and results
in improved clinical outcomes [5–7].
Since filgrastim biosimilars referring to the reference
product Neupogen® are authorized in Europe since 2009
and in the US since 2015, no biosimilars of pegfilgrastim
are approved yet although some compounds are in dif-
ferent stages of development [8–10]. The development
of biosimilars is regulated through specific guidelines to
guarantee similarity with the reference product in qual-
ity, pharmacokinetics, −dynamics, and clinical efficacy as
well as the safety profile [11–14].
We are reporting here the results of a clinical
study comparing efficacy and safety of the proposed
biosimilar RGB-02 with the reference compound
Neulasta® (hereinafter referred to as reference). This
phase III study was designed as prospective, random-
ized, double-blind, parallel-group, multinational,
multicentric trial to demonstrate confirmatory
equivalence in terms of pharmacodynamic and clin-
ical parameters in breast cancer patients receiving
docetaxel/doxorubicin as myelosuppressive chemo-
therapy combination.
Methods
Between January 2014 and April 2015, we included 238
patients with breast cancer in 35 centers (located in
Hungary, Romania, Czech Republic, Bulgaria, Croatia,
Serbia, Russia, Ukraine) receiving chemotherapy on Day
1 of each cycle with 60mg/m2 doxorubicin infusion
followed by 75mg/m2 docetaxel (EudraCT number
2013–003166-14). The study protocol considered all
relevant regulatory and scientific guidelines [15–17] and
was approved by all involved national regulatory author-
ities and ethics committees. The performance and super-
vision of this trial followed the principles of Good
Clinical Practice (GCP) as laid down in ICH E 6 [18].
No interim analysis was performed and no Data Moni-
toring Committee operated in this study.
Patients
The study population included chemotherapy-naïve
women ≥18 and ≤ 65 years of age with invasive breast
cancer (Stage IIB and III) appropriate for combined
treatment with doxorubicin/ docetaxel in the neo−/adju-
vant treatment setting. Additional inclusion criteria were
Eastern Cooperative Oncology Group (ECOG) perform-
ance status 0 or 1 and adequate bone marrow function,
as indicated by absolute neutrophil count (ANC) ≥ 1.5 ×
109/L, platelet count ≥100 × 109/L, and Hemoglobin > 8
g/dL; adequate renal and hepatic function with an esti-
mated creatinine clearance ≥50mL/min (Cockcroft--
Gault method), bilirubin, aspartate transaminase, alanine
transaminase < 1.5 x upper limit of normal (ULN), and
Alkaline phosphatase < 2.5 x ULN. Women with child-
bearing potential had to present a negative urine preg-
nancy test and had to agree to use 2 reliable methods of
contraception during treatment period and for 3 months
thereafter. Written informed consent had to be given
prior to any study-related procedure. Main exclusion cri-
teria were any other malignancy within 5 years prior to
randomization, with the exception of cervical carcinoma
in situ, non-melanoma skin cancer, or superficial bladder
tumors (Ta, Tis, or T1) that had been successfully and
curatively treated; active infection or systemic
anti-infective treatment, radiation therapy within 4
weeks prior to randomization; past exposure to any
G-CSFs; concurrent anti-cancer therapy, concomitant
treatment with bisphosphonates; prior bone marrow or
stem cell transplantation; history or presence of sickle
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cell disease, and significant cardiovascular disease (cau-
tion especially for doxorubicin).
Randomization and study treatment
Eligible patients were randomly assigned to receive the
study drugs (6 mg s.c. of either RGB-02 or reference) in
a 1:1 ratio via an interactive voice/web response system
(IXRS). On day 1 of each treatment cycle, all patients re-
ceived 60 mg/m2 doxorubicin followed 1 h later by an
intravenous infusion of 75 mg/m2 docetaxel. Chemother-
apy was to be repeated every 3 weeks for up to 6 cycles.
Patients were dosed with the study drugs approximately
24 h after chemotherapy was initiated for each cycle.
Study procedures
The study design was set up in a double blind fashion
for the first 2 treatment cycles to demonstrate confirma-
tory efficacy followed by an open-label safety assessment
during treatment the subsequent cycles. Patients in the
reference arm were switched to open-label RGB-02
starting with cycle 3. After the initial 3-weeks-screening
period and baseline visits, patients were scheduled for 4
chemotherapy cycles (and 2 additional if deemed neces-
sary) each requiring 12 study visits within 3 weeks
followed by a final safety assessment 6 months after
treatment start. Pre-defined hematology blood samplings
to determine the absolute neutrophil count for efficacy
assessment were performed on Days − 1, 1, 2, 3, daily
from Day 5 to Day10 and on Days 14 and 18. All pa-
tients underwent a baseline clinical examination that in-
cluded physical examination, pregnancy testing, safety
monitoring including hematology data (Hemoglobin;
WBC count, lymphocytes (absolute), neutrophils (abso-
lute), platelets); testing of hepatic function (aspartate
aminotransferase, alanine aminotransferase, and biliru-
bin), lactate dehydrogenase, albumin, blood urea nitro-
gen, uric acid, creatinine clearance.
Blood sampling for immunogenicity assessments of
pegfilgrastim was performed at Day − 1 of Cycles 1, 3
and 4, before any study treatment was administered and
at the end of Cycle 4 and at follow-up. A stepwise ap-
proach was established for immunogenicity assessment,
namely all samples were analyzed with screening assays
for anti-RGB-02 and anti Neulasta® antibodies. The sam-
ples assessed positive with the screening assays were to
be analyzed with confirmatory assays and the confirmed
positive samples would have been analyzed with a
cell-based neutralizing assay. Immunogenicity assays
used were developed and validated in line with the ap-
plicable guidelines and recommendations [14, 19, 20].
Study outcomes
The primary efficacy variable was the mean duration of
severe neutropenia (DSN) in chemotherapy cycle 1
whereas DSN was defined as the number of consecutive
days in which a patient had an ANC < 0.5 × 109/L.
Other secondary outcomes comprised the duration of
severe neutropenia (ANC < 0.5 × 109/L) in Cycles 2, 3
and 4, the incidence of severe neutropenia as well as fe-
brile neutropenia in Cycles 1 and 2, time to ANC recov-
ery and the depth of ANC nadir in Cycles 1 and 2.
The incidence of febrile neutropenia was based on the
ESMO definition of an oral temperature > 38.5 °C or 2
consecutive readings of > 38.0 °C for 2 h and an ANC <
0.5 × 109/L (or expected to fall below 0.5 × 109/L), whereas
the overall incidence of febrile neutropenia included be-
yond the ESMO definition any administration of systemic
antibiotics if treatment with the antibiotics was com-
menced while the ANC was under 1.5 × 109/L [21].
The safety assessment was performed by continuously
evaluating adverse events according Common Termin-
ology Criteria for Adverse Events (CTCAE), Version
4.03. Further safety assessments included physical exam-
inations with special regard to the site of pegfilgrastim
injection, vital signs, ECG, pulse oximetry and laboratory
tests conducted at baseline and at defined time points
post dose. Hematology parameters were assessed on
Days 1, 3, 5–10, 14 and 18, while the timing of other lab
tests varied depending on the parameter. A follow-up
visit was performed 6months after individual study
start.
Statistical analysis
The sample size of 111 evaluable patients per treatment
arm was determined based on an equivalence test of
means using two 1-sided tests on data from a
parallel-group design in order to achieve 90% power at
5% significance level when the true difference between
the means was assumed to be 0.25, the standard devi-
ation (std) was assumed to be 1.70, and the equivalence
limits were − 1.00 and 1.00 days.
The primary efficacy variable was the duration of se-
vere neutropenia, defined as ANC < 0.5 × 109/L, in the
first cycle of chemotherapy. The difference in mean dur-
ation of severe neutropenia between the 2 treatment
arms and the 2-sided 95% confidence interval (CI) for
the difference between means was calculated using an
analysis of covariance (ANCOVA) model with treatment,
country, chemotherapy treatment setting (neoadjuvant
or adjuvant) as factors, and baseline ANC value (value at
Day − 1, Cycle 1) as covariate in the model.
If the upper limit of the 95% CI for the difference in
means was ≤1 day and the lower bound of the CI for the
difference in means was ≥ − 1 day, then the means in the
2 arms were to be considered equivalent. A similar ana-
lysis was performed for Cycle 2.
The duration of severe neutropenia in Cycles 3 and 4
as well as the depth of ANC nadir in Cycles 1 and 2
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were summarized using descriptive statistics. An
ANCOVA analysis was also performed for the difference
in depth of ANC nadir.
The difference in the incidence of patients with febrile
neutropenia in Cycles 1 and 2 between the 2 treatment
arms with associated 95% CI was presented. Time to
ANC recovery in Cycles 1 and 2 was analyzed using
Kaplan-Meier life table methods. The analyses were per-
formed using the protocol definition for ANC recovery
(number of days from any ANC value < 0.5 × 109/L to
ANC ≥ 2 × 109/L) and repeated for the alternative defin-
ition (number of days from the date of the lowest mea-
sured ANC value to ANC ≥ 2 × 109/L). The primary data
set for efficacy analysis was the per-protocol (PP) popu-
lation; the full analysis set (FAS) was analysed in
addition for demonstrating robustness of data. All pa-
tients who received at least one dose of a study medica-
tion were included in the safety analysis. Safety variables
were summarized by treatment arm. All statistical ana-
lyses were performed using SAS 9.2 software.
Results
A total of 239 patients were randomized (1:1) to receive
either RGB-02 or the reference product prior to
undergoing chemotherapy at 35 study centers. One pa-
tient was excluded (this patient randomized to the com-
parator arm did not meet inclusion criteria and
discontinued without receiving study medication) leav-
ing 238 patients in the FAS (Full analysis set) population,
of whom 121 received RGB-02 and 117 received refer-
ence product. The FAS collective also served as safety
data set, detailed patient disposition is listed in Fig. 1.
There were generally no differences in patient charac-
teristics at baseline between groups (Table 1). Stage of
breast cancer was IIB in 47.9% of patients and III in
50.8% of patients, with no differences observed between
study arms. Adjuvant chemotherapy setting was more
common than neoadjuvant in the RGB-02 arm (57.9 and
42.1%, respectively), slightly different - but not clinically
meaningful - to the comparator arm (adjuvant: 50.4%,
neoadjuvant: 49.6%). Both groups were comparable re-
garding medical history, concomitant medication, and
surgical interventions for the underlying breast cancer.
Primary efficacy endpoint
Therapeutic equivalence could be demonstrated be-
tween RGB-02 and the reference pegfilgrastim with
Fig. 1 Patient flow. Note: One of the adverse events (AEs) leading to withdrawal during Cycle 1 in the RGB-02 arm resulted in death after
patient withdrawal
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95% CIs within the predefined margins of ±1 day con-
firming equivalence.
The mean duration of severe neutropenia (DSN, de-
fined as the number of days from the first ANC value <
0.5 × 109/L until increasing back ≥0.5 × 109/L) in the PP
collective during cycle 1 was comparable in the RGB-02
arm (1.7 ± 1.14 days) and the reference arm (1.6 ± 1.31
days). The LS Means (95% CI) were 1.5 (1.2, 1.8) and 1.4
(1.1, 1.7) days, respectively. The LS Mean for the differ-
ence in duration of severe neutropenia was 0.1 days
(95% CI: -0.2, 0.4), identical to that observed in the FAS
population. In cycle 2 the DSN declined equally to 0.7
days for both compounds (Table 2). The mean duration
of severe neutropenia in Cycles 3 and 4, after patients in
the reference arm switched to RGB-02, was < 1 day in
the RGB-02 arm (0.9 days) and the reference arm
switched to RGB-02 (0.6 days), indicating that the switch
from reference to RGB-02 treatment did not increase
the patient’s risk to develop longer lasting grade 4
neutropenia.
The similarity of results in the primary efficacy vari-
able between the PP population and the FAS further
supports the observed equivalent effect and robustness
of data.
Secondary efficacy endpoints
Neither statistically significant nor clinically relevant dif-
ferences were detected in secondary endpoints between
treatment groups.
The mean daily ANC values for both groups in Cycle
1 were almost identical (Fig. 2).
Most patients experienced severe neutropenia (defined
as ANC < 0.5 × 109/L) during cycle 1. The incidence of
severe neutropenia decreased in cycle 2 compared to
cycle 1 in both treatment groups with no statistical sig-
nificant differences, for RGB-02 from 84.6% (99 patients)
to 54.1% (60 patients) and for the comparator groups
from 77.0% (87 patients) to 43.7% (45 patients)
(Table 3).








White 120 (99.2) 117 (100) 237 (99.6)
Asian 1 (0.8) 0 1 (0.4)
Age (years)
Mean (std) 51.0 (8.20) 51.2 (9.56) 51.1 (8.88)
Weight (kg)
Mean (std) 72.17 (14.049) 74.83 (15.240) 73.48 (14.676)
Height (cm)
Mean (std) 163.3 (6.58) 163.5 (6.29) 163.4 (6.43)
BSA (m2)
Mean (std) 1.791 (0.1718) 1.815 (0.1812) 1.803 (0.1765)
Stage of disease [n (%)]
Stage IIB 58 (47.9) 56 (47.9) 114 (47.9)
Stage III 61 (50.4) 60 (51.3) 121 (50.8)
Chemotherapy treatment [n (%)]
Neoadjuvant 51 (42.1) 58 (49.6) 109 (45.8)
Adjuvant 70 (57.9) 59 (50.4) 129 (54.2)
BSA body surface area; std.standard deviation
Table 2 Duration of Severe Neutropenia
RGB-02 Reference Difference(RGB-02 - Reference)
Cycle 1, PP population
n 112 111
Mean (SD) 1.7 (1.14) 1.6 (1.31)
Least squares mean (95% CI) 1.5 (1.2, 1.8) 1.4 (1.1, 1.7) 0.1 (−0.2, 0.4)
Cycle 1, FAS
n 121 117
Mean (SD) 1.8 (1.28) 1.7 (1.45)
Least squares mean (95% CI) 1.6 (1.3, 1.9) 1.4 (1.1, 1.7) 0.1 (−0.2, 0.4)
Cycle 2, PP population
n 111 100
Mean (SD) 0.7 (0.81) 0.7 (0.97)
Least squares mean (95% CI) 0.7 (0.4, 0.9) 0.6 (0.4, 0.8) 0.1 (−0.2, 0.3)
Cycle 2, FAS
n 117 116
Mean (SD) 0.7 (0.81) 0.9 (1.31)
Least squares mean (95% CI) 0.5 (0.3, 0.8) 0.8 (0.5, 1.0) -0.2 (−0.5, 0.1)
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During Cycle 1, the observed incidence and the overall
incidence of febrile neutropenia including cases meeting
the ESMO criteria and those who started systemic anti-
biotic treatment was similar in both groups with 5 pa-
tients [4.3%] and 10 patients [8.5%]) in the RGB-02 arm
and 4 patients [3.5%] and 8 patients [7.1%]) in the refer-
ence arm. During Cycle 2, no febrile neutropenia was
observed in any of the treatment arm except one overall
febrile neutropenia case in the RGB-02 group (Table 4).
There were no significant differences between groups
regarding mean time to ANC recovery (defined as recov-
ery from any ANC value < 0.5 × 109/L to ANC ≥ 2 × 109/
L). During Cycle 1, mean time to recovery was 3.4 ±
1.84 days in the RGB-02 arm and 3.7 ± 1.88 days in
the reference arm; during Cycle 2, mean time to re-
covery was 2.8 ± 1.09 days and 3.4 ± 2.11 days, respect-
ively. The recovery from the date of the lowest
measured ANC value was comparable between
groups, too (Fig. 2). Also, no clinically meaningful dif-
ference was found when comparing the mean depth
of ANC nadir in Cycle 1 and 2.
Safety
When analysing the safety population one has to take
into account that the reference drug was given only for
the double-blind period of the first 2 Cycles. All patients
from that group received thereafter RGB-02 for cycles
3–6. The safety population for the comparative safety
analysis (Table 5) comprised 238 women (RGB-02 = 121,
reference = 117) whereas altogether 234 women received
995 doses of RGB-02 throughout the course of the
study. In total, 204/234 (87.2%) patients treated with
RGB-02 had at least 1 adverse event (AE).
Fig. 2 Mean ANC Values by Day and Treatment Arm – Cycle 1
Table 3 Incidence of Severe Neutropenia
RGB-02 Reference Difference(RGB-02 - Reference)
Cycle 1, PP population
n 117 113
n (%) with severe neutropenia 99 (84.6) 87 (77.0)
Proportion (95% CI) with severe neutropenia 0.846 (0.768, 0.906) 0.770 (0.681, 0.844) 0.076 (−0.055, 0.204)
Cycle 2, PP population
n 111 103
n (%) with severe neutropenia 60 (54.1) 45 (43.7)
Proportion (95% CI) with severe neutropenia 0.541(0.443, 0.636) 0.437(0.339, 0.538) 0.104(−0.031, 0.236)
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The cumulative incidence of adverse events was simi-
lar between both groups.
During Cycles 1 and 2, 80.2% treatment-emergent ad-
verse events (TEAE) were reported in the RGB-02 arm
(n = 97) compared to 93.2% in the reference arm (n =
109). Similarly, the number of patients with IMP-related
AEs was marginally lower in the RGB-02 arm (17 pa-
tients [14.0%]) compared to the reference arm (27 pa-
tients [23.1%]). The most frequent pegfilgrastim-related
AE was bone pain, slightly less frequently reported in
the RGB-02 arm (14 patients [11.6%]) compared to the
reference arm (20 patients [17.1%]).Other musculoskel-
etal and connective tissue disorders included arthralgia
in the RGB-02 arm (2 patients [1.7%]. Myalgia (3 pa-
tients [2.6%], pain in extremity and spinal pain (2 pa-
tients [1.7%] each) were reported in the reference arm
only.
Serious adverse events (SAE) were reported during the
double-blind period at Cycles 1 and 2 in 8.3% of the
RGB-02 arm and 6.8% of the reference arm cases, none
of them related to pegfilgrastim (Table 6). The most fre-
quent SAE was febrile neutropenia: 4.1% of patients in
the RGB-02 arm and 5.1% of patients in the reference
arm. There were 2 deaths reported in the RGB-02 arm,
none of them were related to the investigational
medicinal product (IMP). Causes for death were metas-
tases to central nervous system and viral infection.
Immunogenicity
The screening assay test was negative in 96.1% of im-
munogenicity samples for the double blind treatment
period. However, all positive screening tests were negative
in the confirmatory test. Neutralising assay tests were not
performed since none of the confirmatory tests were posi-
tive. In the open-label period including the 6-month fol-
low - up, the screening assay test was negative in a range
of 96.3–98.2% of all obtained immunogenicity samples at
different time points. Again, positive screening tests
turned out to be negative in the confirmatory test, there-
fore no neutralising assay tests were performed.
In conclusion, no patients of either treatment group
had true positive immunogenicity results. The
re-treatments did not increase the incidence of positive
immune responses and the switch from reference treat-
ment to RGB-02 did not provoke any immunogenic
response.
Discussion
This study was designed to confirm RGB-02 as a safe
and effective biosimilar to the reference pegfilgrastim
Table 4 Observed Incidence of Febrile Neutropenia
RGB-02 Reference Difference(RGB-02 - Reference)
Cycle 1, PP population
n 117 113
n (%) with febrile neutropenia 5 (4.3) 4 (3.5)
Proportion (95% CI) with febrile neutropenia 0.043 (0.014, 0.097) 0.035(0.010, 0.088) 0.007(−0.123, 0.137)
Cycle 2, PP population
n 111 103
n (%) with febrile neutropenia 0 0





Number (%) of patients with:
Any AE 111 (91.7) 113 (96.6)
Any Grade≥ 3 AE 23 (19.0) 18 (15.4)
Any AE related to IMP 26 (21.5) 32 (27.4)
Any serious AE 13 (10.7) 12 (10.3)
Any IMP-related serious AE 0 0
Any AE leading to withdrawal 2 (1.7) 4 (3.4)
Any IMP-related AE leading to withdrawal 0 0
Any AE with an outcome of death 2 (1.7) 0
Any IMP-related AE with an outcome of death 0 0
Any injection site reaction AE 2 (1.7) 2 (1.7)
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(Neulasta®) in a chemotherapeutic patient setting. The
selected population received standard treatment with
docetaxel/doxorubicin chemotherapy combination for
breast cancer and was in close concordance to the popu-
lations chosen in former clinical trials with pegfilgrastim
and biosimilar filgrastim trials. The chosen chemother-
apy combination is known to cause severe neutropenia
in almost all treated patients [22].
In this multinational, prospective, randomized
double-blind study, therapeutic equivalence could be
demonstrated between RGB-02 and the reference pegfil-
grastim measuring the duration of severe neutropenia
(DSN). The difference between treatments of 0.1 days
and the 95% CI (− 0.2, 0.4) lies well inside the predefined
range of ±1 day. The mean DSN observed in RGB-02
(1.7 ± 1.14 days) and the reference arm (1.6 ± 1.31 days)
was in line with published data (mean DSN of 1.3–1.8
days) [23–27]. The analysis of secondary endpoints con-
firmed the positive findings for RGB-02. There was no
clinically meaningful difference between treatment
groups and the results showed similar evidence of bene-
fit. The incidence and duration of severe neutropenia as
well as episodes of fever and treatment with antibiotics
were almost identical in both groups.
The safety results were comparable with published
data for this chemotherapeutic regimen and pegfilgras-
tim [27, 28]. No new safety concerns were reported in
this trial and RGB-02 was well tolerated with no related
serious adverse events. Similarly, the incidence and se-
verity of bone pain associated with the use of pegfilgras-
tim was comparable between treatment arms and was
similar to previous studies [29].
Immunogenicity can cause problems for biologics. Pa-
tients may produce antidrug antibodies (ADAs), which
might lead to efficacy loss or adverse reactions. No pa-
tients had true positive immunogenicity results for
RGB-02 or the reference pegfilgrastim, i.e., no immuno-
genic response to the study drugs was observed during
the study as no anti-pegfilgrastim antibodies were de-
tected in the study.
Pegylated filgrastim when compared to filgrastim ex-
erts a longer half-life and allows therefore a single dose
per cycle thus increasing patient compliance and thereby
reducing the risk of febrile neutropenic episodes.
Conclusions
Therapeutic treatment equivalence between RGB-02 and
Neulasta® was demonstrated. The analysis of the primary
as well as all secondary efficacy endpoints did not reveal
any statistically significant or clinically meaningful differ-
ences between the treatment arms. The safety profile of
RGB-02 is comparable with the reference pegfilgrastim
and no immunogenicity was found, even after switching
from the originator product to RGB-02.
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Any Serious Adverse Event in Cycle 1 or 2 10 (8.3) 8 (6.8)
Blood and lymphatic system disorders 5 (4.1) 7 (6.0)
Febrile neutropenia 5 (4.1) 6 (5.1)
Neutropenia 0 2 (1.7)
Infections and infestations 2 (1.7) 1 (0.9)
Cystitis 0 1 (0.9)
Neutropenic infection 1 (0.8) 0
Oesophageal candidiasis 1 (0.8) 0
Vascular disorders 2 (1.7) 0
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Haemorrhagic duodenitis 1 (0.8) 0
Erosive duodenitis 1 (0.8) 0
Neoplasms benign, malignant and unspecified (including cysts and polyps) 1 (0.8) 0
Metastases to central nervous system 1 (0.8) 0
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